Drugs induced pulmonary arterial hypertension

Presse Medicale

Volumn 42, Issue 9 PART2, 2013, Pages

  Seferian, Andrei ^a,b,c   Chaumais, Marie Camille ^a,b,c   Savale, Laurent ^a,b,c   Günther, Sven ^a,b,c   Tubert Bitter, Pascale ^d   Humbert, Marc ^a,b,c   Montani, David ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOREX; AMPHETAMINE; ANOREXIGENIC AGENT; BENFLUOREX; BETA INTERFERON; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; DASATINIB; DECONGESTIVE AGENT; DEXFENFLURAMINE; FENFLURAMINE; GROWTH FACTOR; INTERFERON; MAZINDOL; PERGOLIDE; PHENTERMINE; PHENYLPROPANOLAMINE; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN;

ASTHMA; BONE MARROW SUPPRESSION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CARDIOMYOPATHY; CHRONIC MYELOID LEUKEMIA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HUMAN; KIDNEY FAILURE; LIVER FAILURE; LUNG INFILTRATE; LUNG VASCULAR RESISTANCE; NARCOLEPSY; OBESITY; PLEURA EFFUSION; POLYNEUROPATHY; PULMONARY HYPERTENSION; RISK FACTOR; SARCOIDOSIS; SHORT SURVEY; SMOOTH MUSCLE FIBER;

EID: 84884207194     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.07.005     Document Type: Short Survey

References (63)

1. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 1997, 336(2):111-117. Epub 1997/01/09.
2. Simonneau G., Robbins I.M., Beghetti M., Channick R.N., Delcroix M., Denton C.P., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(Suppl.1):S43-S54. Epub 2009/07/09.
3. Gurtner H.P. Chronic pulmonary hypertension of vascular etiology, plexogenic pulmonary arteriopathy and the appetite depressant Aminorex: lessons from an epidemic. Swiss Med Wkly 1985, 115(24):818-827. Epub 1985/06/15.
4. Gurtner H.P. Aminorex and pulmonary hypertension. A review. Cor et vasa 1985, 27(2-3):160-171. Epub 1985/01/01.
5. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30(20):2493-2537. Epub 2009/08/29.
6. Kay J.M., Smith P., Heath D. Aminorex and the pulmonary circulation. Thorax 1971, 26(3):262-270. Epub 1971/05/01.
7. Simonneau G., Fartoukh M., Sitbon O., Humbert M., Jagot J.L., Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998, 114(Suppl.3):195S-199S. Epub 1998/09/19.
8. Eddahibi S., Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res 2002, 3:9. Epub 2002/01/25.
9. Eddahibi S., Humbert M., Fadel E., Raffestin B., Darmon M., Capron F., et al. Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 2002, 121(Suppl.3):97S-98S. Epub 2002/03/15.
10. Eddahibi S., Raffestin B., Hamon M., Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?. J Lab Clin Med 2002, 139(4):194-201. Epub 2002/05/25.
11. Herve P., Launay J.M., Scrobohaci M.L., Brenot F., Simonneau G., Petitpretz P., et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995, 99(3):249-254. Epub 1995/09/01.
12. Loogen F., Worth H., Schwan G., Goeckenjan G., Losse B., Horstkotte D. Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor et vasa 1985, 27(2-3):111-124. Epub 1985/01/01.
13. Douglas J.G., Munro J.F., Kitchin A.H., Muir A.L., Proudfoot A.T. Pulmonary hypertension fenfluramine. Br Med J 1981, 283(6296):881-883. Epub 1981/10/03.
14. Brenot F., Herve P., Petitpretz P., Parent F., Duroux P., Simonneau G. Primary pulmonary hypertension fenfluramine use. Br Heart J 1993, 70(6):537-541. Epub 1993/12/01.
15. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 335(9):609-616. Epub 1996/08/29.
16. Souza R., Humbert M., Sztrymf B., Jais X., Yaici A., Le Pavec J., et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 2008, 31(2):343-348. Epub 2007/10/26.
17. Krzentowski G., Pallikarakis N., Lacroix M., Pirnay F., Mosora F., Luyckx A., et al. Effect of benfluorex on the metabolic fate of an oral glucose load in obese subjects with reduced glucose tolerance (author's transl). Therapie 1979, 34(4):445-455. Epub 1979/07/01.
18. Boutet K., Frachon I., Jobic Y., Gut-Gobert C., Leroyer C., Carlhant-Kowalski D., et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009, 33(3):684-688. Epub 2009/03/03.
19. Frachon I., Etienne Y., Jobic Y., Le Gal G., Humbert M., Leroyer C. Benfluorex and unexplained valvular heart disease: a case-control study. PloS one 2010, 5(4):e10128. Epub 2010/04/21.
20. Savale L., Chaumais M.C., Cottin V., Bergot E., Frachon I., Prevot G., et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012, 40(5):1164-1172. Epub 2012/04/24.
21. Schaiberger P.H., Kennedy T.C., Miller F.C., Gal J., Petty T.L. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 1993, 104(2):614-616. Epub 1993/08/01.
22. Yakel D.L., Eisenberg M.J. Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J 1995, 130(2):398-399. Epub 1995/08/01.
23. Collazos J., Martinez E., Fernandez A., Mayo J. Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med 1996, 90(3):171-174. Epub 1996/03/01.
24. van Wolferen S.A., Vonk Noordegraaf A., Boonstra A., Postmus P.E. Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping. Nederlands tijdschrift voor geneeskunde 2005, 149(23):1283-1288. Epub 2005/06/18.
25. Chin K.M., Channick R.N., Rubin L.J. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. Chest 2006, 130(6):1657-1663. Epub 2006/12/15.
26. Tseng Y.T., Padbury J.F. Expression of a pulmonary endothelial norepinephrine transporter. J Neural Transm 1998, 105(10-12):1187-1191. Epub 1999/02/03.
27. Salvi S.S. Alpha1-adrenergic hypothesis for pulmonary hypertension. Chest 1999, 115(6):1708-1719. Epub 1999/06/23.
28. Marcos E., Fadel E., Sanchez O., Humbert M., Dartevelle P., Simonneau G., et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004, 94(9):1263-1270. Epub 2004/04/03.
29. Wellman P.J., Maher T.J. Synergistic interactions between fenfluramine and phentermine. Obes Rev 1999, 23(7):723-732. Epub 1999/08/24.
30. Rich S., Rubin L., Walker A.M., Schneeweiss S., Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000, 117(3):870-874. Epub 2000/03/14.
31. Hagiwara M., Tsuchida A., Hyakkoku M., Nishizato K., Asai T., Nozawa Y., et al. Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report. Circ J 2000, 64(3):218-221. Epub 2000/03/25.
32. Nittur N., Konofal E., Dauvilliers Y., Franco P., Leu-Semenescu S., Cock V.C., et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med 2013, 14(1):30-36. Epub 2012/10/06.
33. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14):1031-1037. Epub 2001/04/05.
34. Ghofrani H.A., Morrell N.W., Hoeper M.M., Olschewski H., Peacock A.J., Barst R.J., et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182(9):1171-1177. Epub 2010/06/29.
35. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109(6):2303-2309. Epub 2006/12/02.
36. Quintas-Cardama A., Kantarjian H., Jones D., Nicaise C., O'Brien S., Giles F., et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007, 109(2):497-499. Epub 2006/09/23.
37. Mattei D., Feola M., Orzan F., Mordini N., Rapezzi D., Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplan 2009, 43(12):967-968. Epub 2008/12/24.
38. Rasheed W., Flaim B., Seymour J.F. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009, 33(6):861-864. Epub 2008/11/07.
39. Dumitrescu D., Seck C., ten Freyhaus H., Gerhardt F., Erdmann E., Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011, 38(1):218-220. Epub 2011/07/02.
40. Montani D., Bergot E., Gunther S., Savale L., Bergeron A., Bourdin A., et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012, 125(17):2128-2137. Epub 2012/03/28.
41. Guignabert C., Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J 2013, 41(1):3-4. Epub 2013/01/02.
42. Dusheiko G.M., Roberts J.A. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995, 22(6):1863-1873. Epub 1995/12/01.
43. Tyring S.K. Interferons: biochemistry and mechanisms of action. Am J Obstet Gynecol 1995, 172(4 Pt 2):1350-1353. Epub 1995/04/01.
44. Weissmann C., Weber H. The interferon genes. Prog Nucleic Acid Res Mol Biol 1986, 33:251-300. Epub 1986/01/01.
45. Davis G.L., Balart L.A., Schiff E.R., Lindsay K., Bodenheimer H.C., Perrillo R.P., et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.Hepatitis Interventional Therapy Group. N Engl J Med 1989, 321(22):1501-1506. Epub 1989/11/30.
46. Brillanti S., Garson J., Foli M., Whitby K., Deaville R., Masci C., et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994, 107(3):812-817. Epub 1994/09/01.
47. Anderson P., Hoglund M., Rodjer S. Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies. Am J Hematol 2003, 73(1):54-58. Epub 2003/04/18.
48. Dhillon S., Kaker A., Dosanjh A., Japra D., Vanthiel D.H. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci 2010, 55(6):1785-1790. Epub 2010/04/23.
49. Hanaoka M., Kubo K., Hayano T., Koizumi T., Kobayashi T. Interferon-alpha elevates pulmonary blood pressure in sheep-the role of thromboxane cascade. Eur J Pharmacol 1999, 370(2):145-151. Epub 1999/05/14.
50. Clerico M., Contessa G., Durelli L. Interferon-beta1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007, 7(4):535-542. Epub 2007/03/22.
51. Caravita S., Secchi M.B., Wu S.C., Pierini S., Paggi A. Sildenafil therapy for interferon-beta-1a-induced pulmonary arterial hypertension: a case report. Cardiology 2011, 120(4):187-189. Epub 2012/01/25.
52. Ledinek A.H., Jazbec S.S., Drinovec I., Rot U. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report. Mult Scler 2009, 15(7):885-886. Epub 2009/05/26.
53. Tazelaar H.D., Myers J.L., Drage C.W., King T.E., Aguayo S., Colby T.V. Pulmonary disease associated with l-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest 1990, 97(5):1032-1036. Epub 1990/05/01.
54. Yakovlevitch M., Siegel M., Hoch D.H., Rutlen D.L. Pulmonary hypertension in a patient with tryptophan-induced eosinophilia-myalgia syndrome. Am J Med 1991, 90(2):272-273. Epub 1991/02/01.
55. Hertzman P.A., Falk H., Kilbourne E.M., Page S., Shulman L.E. The eosinophilia-myalgia syndrome: the Los Alamos Conference. J Rheumatol 1991, 18(6):867-873. Epub 1991/06/01.
56. Smith M.J., Garrett R.H., et al. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation. Inflamm Res 2005, 54(11):435-450. Epub 2005/11/25.
57. Walker A.M., Langleben D., Korelitz J.J., Rich S., Rubin L.J., Strom B.L., et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 2006, 152(3):521-526. Epub 2006/08/23.
58. Barst R.J., Abenhaim L. Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart 2004, 90(7):e42. Epub 2004/06/18.
59. Van Camp G., Flamez A., Cosyns B., Weytjens C., Muyldermans L., Van Zandijcke M., et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004, 363(9416):1179-1183. Epub 2004/04/15.
60. Evrard F., Dupuis M., Muller T., Jacquerye P. Isolated pulmonary hypertension and pergolide. Rev Neurol 2008, 164(3):278-279. Epub 2008/04/15.
61. Tiefenbrunn L.J., Riemenschneider T.A. Persistent pulmonary hypertension of the newborn. Am Heart J 1986, 111(3):564-572. Epub 1986/03/01.
62. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354(6):579-587. Epub 2006/02/10.
63. Kieler H., Artama M., Engeland A., Ericsson O., Furu K., Gissler M., et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012, 344:d8012. Epub 2012/01/14.